After nine years of grinding, Replit finally found its market. Can it keep it?

While AI coding startups like Cursor close brow-raising rounds on barely three years of existence, Replit's path to a $3 ...
Zacks Investment Research on MSN

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...